Status:
TERMINATED
A Single Dose Study Investigating the Elimination as Well as the Tolerability of PD 0332334 in Healthy Subjects as Compared to Patients With Impaired Kidney Function.
Lead Sponsor:
Pfizer
Conditions:
Renal Insufficiency
Pharmacokinetics
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
1. To investigate the effect of kidney function on the elimination of a single dose of PD 0332334 from the body. 2. To investigate the safety and tolerability of a single dose of PD 0332334 in patient...
Detailed Description
Additional Study Purpose Details: Investigation of the pharmacokinetics, safety, and tolerability of a single dose of PD 0332334 in patients with impaired renal function. On February 23rd 2009, a dec...
Eligibility Criteria
Inclusion
- Healthy volunteers OR subjects with kidney impairment
Exclusion
- Receiving hemodialysis
- clinically significant or unstable medical disease other than kidney disease
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00721422
Start Date
August 1 2008
End Date
February 1 2009
Last Update
February 17 2010
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Cypress, California, United States, 90630
2
Pfizer Investigational Site
Miami, Florida, United States, 33169